Business
Mesoblast shares savaged on poor COVID trial results – Sydney Morning Herald
The stem cell treatment hopeful plunged 41 per cent at the open after revealing its COVID research was unlikely to meet its goals.
The company, will complete the study, which had been aiming to recruit 300 patients, using the 223 patients already enrolled.
Its the second piece of tough news for Mesoblast, which is backed by high profile investors including billionaire Alex Waislitz, to be released this week, after phase 3 trial results of its heart failure drug caused the stock to plunge at the start of the week. The company released data on Tuesday showing its other product, Revascor, showed reduction in mortality of up to…
-
Noosa News22 hours agoItalian Film Festival, Brisbane: All the Details
-
Noosa News17 hours agoKatter and pregnant wife crash-land plane in outback Qld
-
Noosa News17 hours agoFollowing Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’
-
Business24 hours ago7% lift in profits and guidance upgrade